All In Biotech

Free tool

FDA Approval Tracker

Original approvals of brand-name drugs and biologics (NDAs and BLAs) and efficacy supplements, which add a new use, population or dose. Approvals by CBER (most vaccines, blood products and cell and gene therapies) are not in Drugs@FDA and so are missing.

Last checked: Nov 19, 2026Latest source record: Jun 26, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations

Reset

Matching approvals

186

2015 to 2026

Breakthrough

186

Accelerated

67

Priority review

174

Orphan

137

By year

NDAs and BLAs matching the filters.

  • NDA
  • BLA
View as table
YearNDABLA
201575
201663
2017125
2018108
2019114
2020158
2021144
202297
202375
2024126
2025175
202624

186 approvals

Newest first. Hover a badge for what it means.

  • Lumvoa (Veligrotug-Vvze) · Viridian Therapeutics INCJun 26, 2026
    Original approval · BLA 761530NovelBreakthrough therapyPriority reviewApproval letter

    To treat thyroid eye disease

  • Hepcludex (Bulevirtide-Gmod) · Gilead Sciences INCMay 22, 2026
    Original approval · BLA 761468NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis

  • Beqalzi (Sonrotoclax) · Beone Medicines USAMay 13, 2026
    Original approval · NDA 220711NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor

  • Avlayah (Tividenofusp Alfa-Eknm) · Denali Therapeutics Inc.Mar 24, 2026
    Original approval · BLA 761485NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)

  • Loargys (Pegzilarginase-Nbln) · Immedica Pharma AbFeb 23, 2026
    Original approval · BLA 761211NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction

  • Zycubo (Copper Histidinate) · Sentynl Theraps INCJan 12, 2026
    Original approval · NDA 211241NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat Menkes disease

  • Yartemlea (Narsoplimab-Wuug) · Omeros CorpDec 23, 2025
    Original approval · BLA 761152NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat hematopoietic stem cell transplant-associated thrombotic microangiopathy

  • Jascayd (Nerandomilast) · Boehringer IngelheimDec 19, 2025
    Original approval · NDA 220449Breakthrough therapyPriority reviewOrphanApproval letter
  • Myqorzo (Aficamten) · CytokineticsDec 19, 2025
    Original approval · NDA 219083NovelBreakthrough therapyOrphanApproval letter

    To treat symptomatic obstructive hypertrophic cardiomyopathy

  • Voyxact (Sibeprenlimab-Szsi) · Otsuka Pharm CO LTDNov 25, 2025
    Original approval · BLA 761434NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To reduce proteinuria in primary immunoglobulin A nephropathy in adults at risk for disease progression

  • Hyrnuo (Sevabertinib) · Bayer HealthcareNov 19, 2025
    Original approval · NDA 219972NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat locally advanced or metastatic non-squamous non-small cell lung cancer with tumors that have activating HER2 tyrosine kinase domain activating mutations in patients who received a systemic therapy

  • Redemplo (Plozasiran Sodium) · ArrowheadNov 18, 2025
    Original approval · NDA 219947NovelBreakthrough therapyOrphanApproval letter

    To reduce triglycerides in adults with familial chylomicronemia syndrome

  • Komzifti (Ziftomenib) · KuraNov 13, 2025
    Original approval · NDA 220305NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options

  • Kygevvi (Doxecitine, Doxribtimine) · Ucb INCNov 3, 2025
    Original approval · NDA 219792NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat thymidine kinase 2 deficiency in patients who start to show symptoms when they are 12 years old or younger

  • Jascayd (Nerandomilast) · Boehringer IngelheimOct 7, 2025
    Original approval · NDA 218764NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat idiopathic pulmonary fibrosis

  • Inlexzo (Gemcitabine Hydrochloride) · Janssen BiotechSep 9, 2025
    Original approval · NDA 219683Breakthrough therapyPriority reviewApproval letter
  • Brinsupri (Brensocatib) · Insmed INCAug 12, 2025
    Original approval · NDA 217673NovelBreakthrough therapyPriority reviewApproval letter

    To treat non-cystic fibrosis bronchiectasis

  • Hernexeos (Zongertinib) · Boehringer IngelheimAug 8, 2025
    Original approval · NDA 219042NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To treat adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy

  • Zegfrovy (Sunvozertinib) · DizalJul 2, 2025
    Original approval · NDA 219839NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, with disease progression on or after platinum-based chemotherapy

  • Datroway (Datopotamab Deruxtecan-Dlnk) · Daiichi Sankyo INCJun 23, 2025
    Original approval · BLA 761464NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
  • Yeztugo (Lenacapavir Sodium) · Gilead Sciences INCJun 18, 2025
    Original approval · NDA 220020NovelBreakthrough therapyPriority reviewApproval letter
  • Yeztugo (Lenacapavir, Lenacapavir Sodium) · Gilead Sciences INCJun 18, 2025
    Original approval · NDA 220018NovelBreakthrough therapyPriority reviewApproval letter
  • Ibtrozi (Taletrectinib Adipate) · NuvationJun 11, 2025
    Original approval · NDA 219713NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat locally advanced or metastatic ROS1-positive non-small cell lung cancer

  • Emrelis (Telisotuzumab Vedotin-Tllv) · Abbvie INCMay 14, 2025
    Original approval · BLA 761384NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To treat locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression after prior systemic therapy

  • Avmapki Fakzynja CO-Pack (Copackaged) (Avutometinib Potassium, Defactinib Hydrochloride) · Verastem INCMay 8, 2025
    Original approval · NDA 219616NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) after prior systemic therapy

  • Penpulimab-Kcqx (Penpulimab-Kcqx) · Akeso BiopharmaApr 23, 2025
    Original approval · BLA 761258NovelBreakthrough therapyOrphanApproval letter

    In combination with either cisplatin or carboplatin and gemcitabine, to treat adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC), or as a single agent while on or after platinum-based chemotherapy and at least one other prior line of therapy

  • Vykat Xr (Diazoxide Choline) · SolenoMar 26, 2025
    Original approval · NDA 216665Breakthrough therapyPriority reviewOrphanApproval letter
  • Journavx (Suzetrigine) · Vertex Pharms INCJan 30, 2025
    Original approval · NDA 219209NovelBreakthrough therapyPriority reviewApproval letter

    To treat moderate to severe acute pain

  • Tryngolza (Autoinjector) (Olezarsen Sodium) · Ionis Pharms INCDec 19, 2024
    Original approval · NDA 218614NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat familial chylomicronemia syndrome

  • Crenessity (Crinecerfont) · NeurocrineDec 13, 2024
    Original approval · NDA 218820Breakthrough therapyPriority reviewOrphanApproval letter
  • Crenessity (Crinecerfont) · NeurocrineDec 13, 2024
    Original approval · NDA 218808NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat classic congenital adrenal hyperplasia

  • Bizengri (Zenocutuzumab-Zbco) · Merus N.V.Dec 4, 2024
    Original approval · BLA 761352NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat non-small cell lung cancer and pancreatic adenocarcinoma

  • Ziihera (Zanidatamab-Hrii) · Jazz PharmsNov 20, 2024
    Original approval · BLA 761416NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer

  • Revuforj (Revumenib Citrate) · SyndaxNov 15, 2024
    Original approval · NDA 218944NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat relapsed or refractory acute leukemia

  • Itovebi (Inavolisib) · Genentech INCOct 10, 2024
    Original approval · NDA 219249NovelBreakthrough therapyPriority reviewApproval letter

    To treat locally advanced or metastatic breast cancer

  • Miplyffa (Arimoclomol Citrate) · Zevra DenmarkSep 20, 2024
    Original approval · NDA 214927NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat Niemann-Pick disease type C

  • Livdelzi (Seladelpar Lysine) · Gilead Sciences INCAug 14, 2024
    Original approval · NDA 217899NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat primary biliary cholangitis (PBC)

  • Nemluvio (Nemolizumab-Ilto) · Galderma Labs LpAug 12, 2024
    Original approval · BLA 761390NovelBreakthrough therapyPriority reviewApproval letter

    To treat prurigo nodularis

  • Voranigo (Vorasidenib) · ServierAug 6, 2024
    Original approval · NDA 218784NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat Grade 2 astrocytoma or oligodendroglioma

  • Kisunla (Donanemab-Azbt) · Eli Lilly COJul 2, 2024
    Original approval · BLA 761248NovelBreakthrough therapyPriority reviewApproval letter

    To treat Alzheimer's disease

  • Iqirvo (Elafibranor) · IpsenJun 10, 2024
    Original approval · NDA 218860NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat primary biliary cholangitis in combination with ursodeoxycholic acid

  • Imdelltra (Tarlatamab-Dlle) · Amgen INCMay 16, 2024
    Original approval · BLA 761344NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat extensive stage small cell lung cancer

  • Voydeya (Danicopan) · Alexion Pharms INCMar 29, 2024
    Original approval · NDA 218037NovelBreakthrough therapyOrphanApproval letter

    To treat extravascular hemolysis with paroxysmal nocturnal hemoglobinuria

  • Winrevair (Sotatercept-Csrk) · Merck Sharp DohmeMar 26, 2024
    Original approval · BLA 761363NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat pulmonary arterial hypertension

  • Rezdiffra (Resmetirom) · MadrigalMar 14, 2024
    Original approval · NDA 217785NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring

  • Eohilia (Budesonide) · Takeda Pharms USAFeb 9, 2024
    Original approval · NDA 213976Breakthrough therapyPriority reviewOrphanApproval letter
  • Iwilfin (Eflornithine Hydrochloride) · UswmDec 13, 2023
    Original approval · NDA 215500Breakthrough therapyPriority reviewOrphanApproval letter
  • Fabhalta (Iptacopan Hydrochloride) · NovartisDec 5, 2023
    Original approval · NDA 218276NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat paroxysmal nocturnal hemoglobinuria

  • Ogsiveo (Nirogacestat Hydrobromide) · SpringworksNov 27, 2023
    Original approval · NDA 217677NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat adults with progressing desmoid tumors who require systemic treatment

  • Loqtorzi (Toripalimab-Tpzi) · Coherus Biosciences INCOct 27, 2023
    Original approval · BLA 761240NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat recurrent or metastatic nasopharyngeal carcinoma when used together with or following other therapies

Page 1 of 4Older

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.